← All trials
NCT05040126
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 7, 2021
- Primary completion
- Dec 31, 2023
- Completion date
- Mar 31, 2024
- First posted
- Sep 10, 2021
- Last posted
- Nov 9, 2021
- Enrollment
- 400
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Institute for Research in Tuberculosis, Chennai, IndiaLead sponsor
- National Institute for Research in Tuberculosis, Chennai, IndiaReponsible party - principal investigator
- National Institute for Research in Tuberculosis, Chennai, IndiaOverall official - principal investigator
- B. J. Medical College and HospitalCollaborator
- Govt. Medical College, SuratCollaborator
- Sarvodaya Charitable Trust Hospital, Ghatkopar, MumbaiCollaborator
- The international Union Against Tuberculosis and Lung Diseases, ParisCollaborator
- King George's Medical UniversityCollaborator
- Shatabdi Centenary Hospital, Govandi, MumbaiCollaborator
- SN Medical College, AgraCollaborator
- Rajan Babu Institute of Pulmonary Medicine and TuberculosisCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.